The efficacy of inhibiting tumour necrosis factor α and interleukin 1 in patients with rheumatoid arthritis: A meta-analysis and adjusted indirect comparisons

Rheumatology

Volumn 46, Issue 7, 2007, Pages 1140-1147

  Nixon, Richard ^a,b   Bansback, N ^b,c   Brennan, A ^b  

^a MRC BIOSTATISTICS UNIT   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c ST PAUL S HOSPITAL   (Canada)

Author keywords

Biologic agents; Meta analysis; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; CYTOKINE RECEPTOR ANTAGONIST; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE DURATION; DRUG DOSE COMPARISON; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; PROBABILITY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SENSITIVITY ANALYSIS; STATISTICAL MODEL; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; METHOTREXATE; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34447318083     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem072     Document Type: Article

References (47)

1. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001;27:269-81.
2. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358:903-11.
3. Klinkhoff A. Biological agents for rheumatoid arthritis: Targeting both physical function and structural damage. Drugs 2004;64;1267-83.
4. Olsen NJ, Stain CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79.
5. Mpofu S, Fatima F, Moots R.J. Anti-TNF-alpha therapies: They are all the same (aren't they?). Rheumatology (Oxford) 2005;44:271-3.
6. Scallon B, Cai A, Solowski N et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002;301:418-26.
7. Bain B, Brazil M. Adalimumab. Nat Rev Drug Discov 2003;2:693-4.
8. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79.
9. Mpofu S, Fatima F, Moots RJ. Anti-TNF-alpha therapies: They are all the same (aren't they?). Rheumatology (Oxford) 2005;44:271-3.
10. Haraoui B. Differentiating the efficacy of tumor necrosis factor inhibitors. J Rheumatol Suppl 2005;74:3-7.
11. Sutton AJ, Jones DR, Abrams KR, Sheldon TA, Song F. Meta-analysis in health technology assessment. In: Stevens A, Abrams K, Brazier J, Fitzpatrick R, Lilford R, ads. Advanced handbook of methods in evidence based healthcare. London: SAGE Publications, 2000.
12. Kalil AC. New drugs for rheumatoid arthritis. N Engl J Med 2004;351:2659-61.
13. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24.
14. Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and interpreted? Start Med 2002;21:1559-73.
15. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: The health assessment questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
16. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
17. Felson DT, Anderson JJ, Lange ML, Wells G, LaValley MP. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 1998;41:1564-70.
18. Sokka T, Pincus T. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: Methotrexate as the anchor drug in 90% and now DMARD in 30% of patients. J Rheumatol 2002;29:2521-4.
19. Olsen NJ, Stain CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79.
20. Bresnihan B, Alvaro-Gracia JM, Cobby M et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
21. Cohen S, Hurd E, Cush J et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate - results of a twentry-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614-24.
22. Cohen SB, Moreland LW, Cush JJ et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Klneret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004;63:1062-8.
23. Fleischmann RM, Schechtman J, Bennett R et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metlHulL-1ra), in patents with rheumatoid arthritis - a large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003;48:927-34.
24. Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
25. Klareskog L, van der Heljde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet 2004;363:675-81.
26. Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis - a randomized, controlled trial. Ann Intern Med 1999;130:478-86.
27. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
28. St Clair EWS, van der Heijde DMFM, Smolen JS et al.. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis - a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43.
29. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. Lancet 1999;354:1932-9.
30. Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-oontrolled, 52-week trial. Arthritis Rheum 2004;50:1400-11.
31. van de Putte LB, Atkins C, Malaise M et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16.
32. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003;48:35-45.
33. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study - a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
34. Furst DE, Schiff MH, Fleischmann RM et al. Adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563-71.
35. Nixon RM, Bansback N, Brennan A. Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Stat Med. 2006, (in press).
36. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis - the importance of disease duration. Arthritis Rheum 2000;43:22-9.
37. Drossaers-Bakker KW, Zwinderman AH, Vlieland TPMV et al. Long-term outcome in rheumatoid arthritis: A simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup. Arthritis Rheum-Arthritis Care Ras 2002;47:383-90.
38. Gilks WR, Thomas A, Spiegelhalter DJ. A language and program for complex Bayesian modeling. Statistician 1994;43:169-77.
39. Gilks WR, Richardson S, Spiegelhalter DJ. Markov chain Monte Carlo in practice. London: Chapman & Hall, 1999.
40. Hochberg MC, Tracy JK, Flores RH. "Stepping-up" from methotrexate: A systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate. Ann Rheum Dis 2001;60:11151-11154.
41. Buds A, Jobanputra P. The trials of anakinra. Lancet 2004;364:827-8.
42. Aletaha D, Ward MM. Duration of rheumatoid arthritis influences this degree of functional improvement in clinical trials. Ann Rheum Dis 2006;65:227-33.
43. Balsa A, Carmona L, Gonzalez-Alvaro I, Belmonte MA, Tena X, Sanmarti R. Value of Disease Activity Score 28 (DAS28) and DAS28-3 compared to American college of Rheumatology-defined remission in rheumatoid arthritis. J Rheumatol 2004;31:40-6.
44. Phillips BM, Ball C, Sackett DL et al. Levels of evidence and grades of recommendations. Oxford Centre for Evidence Based Medicine, Wxford, 2001 (electronic citation: http:/www.cebm.net/ levels_of_evidence.asp).
45. Gabriel S, Drummond M, Maetzel A et al. OMERACT 6 Economics Working Group Report: A proposal for a reference case for economic evaluation in rheumatoid arthritis. J Rheumatol 2003;30:886-90.
46. Dewitt EM, Glick HA, Albert DA, Joffe MM, Wolfe F. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior. Arch Intern Med 2006;166:57-63.
47. Wailoo A, Brennan A, Bansback N, Nixon R, Wolfe R, Michaud K. Modeling the cost effectiveness of etanercept, adalimumab and anakinra compared to infliximab in the treatment of patients with rheumatoid arthritis in the Medicare program. Available at: http://www.shef.ac.uk/content/1/c6/ 03/90/57/AHRQ%20 final%20report.pdf